Related Experiment Video
Updated: Feb 15, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Chronic Hepatitis C Screening, Evaluation, and Treatment Update in the Age of Direct-Acting Antivirals
11 University of California, San Francisco.
Insights
Hepatitis C virus (HCV) screening is recommended for all adults, presenting an opportunity for workplace outreach. Occupational health nurses can facilitate HCV testing and linkage to care, leveraging new curative treatments.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Background:
- Hepatitis C virus (HCV) is a significant global health concern, affecting millions in the US, with many undiagnosed.
- Workplace screening for bloodborne pathogens (BBP) typically occurs post-exposure, but broader HCV screening is less understood.
- New CDC guidelines recommend universal HCV screening for individuals born between 1945-1965, irrespective of risk factors.
Purpose of the Study:
- To review Hepatitis C virus (HCV) management in the era of direct-acting antivirals (DAAs).
- To highlight the opportunity for workplace-based HCV outreach and screening.
- To emphasize the role of occupational health nurses in HCV identification and care linkage.
Main Methods:
- Review of current HCV epidemiology and diagnostic guidelines.
- Analysis of the impact of direct-acting antiviral (DAA) therapies on HCV treatment.
- Discussion of workplace strategies for HCV education, screening, and referral.
Main Results:
- Direct-acting antivirals (DAAs) offer a cure for Hepatitis C virus (HCV).
- Universal HCV screening recommendations create a new avenue for early detection.
- Worksite interventions can increase HCV awareness and testing.
Conclusions:
- Occupational health nurses are pivotal in identifying potential HCV-positive individuals within the workplace.
- Worksite screening and education programs can improve HCV diagnosis rates.
- Linking identified individuals to specialists ensures access to curative DAA treatment, reducing the HCV burden.
Abstract:
Globally, hepatitis C virus (HCV), the cause of one of the most common infectious diseases, infects approximately 4 million to 5 million Americans with approximately half of infected individuals undiagnosed. Some workplaces screen employees for HCV exposure and other bloodborne pathogens (BBP) after needlestick injuries, but it is not well known whether employers screen employees for HCV without an occupational exposure. New guidelines from the Centers for Disease Control and Prevention (CDC) recommend that all individuals born between 1945 and 1965 should be screened for HCV regardless of risk; this provides an opportunity at the worksite for HCV outreach to employees, dependents, and retirees. To understand this recommendation, the management of HCV in the age of direct-acting antivirals (DAAs) should be reviewed. Now that new DAA treatment can cure HCV, occupational health nurses should identify potential HCV-positive individuals at the worksite via HCV education, screening, testing, and, if positive, linking to specialists for treatment.
Related Concept Videos
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Evaluating Limits by Direct Substitution

